LoginSearch News ArchivesSearch for a SupplierCalendar of events |
Phenomenex Launches Chiral Screening Service
Enantiomers of chiral compounds may have different pharmacological effects in biological systems. Regulations require that enantiomers of all chiral drugs in development be screened separately on their pharmacodynamic and pharmacokinetic properties. "Resolving chiral compounds is relatively difficult, and column selection can be complicated," explained Kari Carlson, brand manager for Phenomenex. "Our Chiral Screening Service eliminates time-consuming guesswork and also gives customers a chance to ‘test-drive' our Lux columns." The Phenomenex team of chiral experts will customize a plan for each screening project, taking into account specific requirements and overall separation goals. Once a project is completed, the customer will receive a report that details the optimal method including information on the chiral stationary phase (CSP) selected for the separation, running conditions and associated chromatograms. Customers can find more information at: http://www.phenomenex.com/chromatographyservices Phenomenex is a global technology leader committed to developing novel separation, purification and analytical chemistry solutions for the life sciences and related industries. Phenomenex's core technologies include products for liquid chromatography, gas chromatography, sample preparation, bulk purification chromatographic media, and chromatography accessories and equipment. For more information on Phenomenex, visit www.phenomenex.com. |
|